Home・Aandelen Lijst・Legend Biotech Corp ADR

Legend Biotech Corp ADR

Gesloten

SectorGezondheidszorg

19.11 1.16

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

18.8

Max

19.34

Belangrijke statistieken
By Trading Economics
Inkomsten	-24M -54M
Verkoop	-2.5M 305M
EPS	-0.15
Winstmarge	-17.851
Werknemers	3,100
EBITDA	-24M -32M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+175.38% upside

Dividenden
By Acuity
Volgende Winsten	11 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-1B 3.7B
Vorige openingsprijs	17.95
Vorige sluitingsprijs	19.11

Nieuwssentiment

By Acuity

100%

320 / 340 Rangschikking in Healthcare

Legend Biotech Corp ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 aug 2026, 22:01 UTC

Shares of Legend Biotech Corp are higher in after-market trading, reflecting gains since Monday's close amid broader market advances in tech and oil-sensitive sectors.

31 jul 2026, 23:56 UTC

Shares of Legend Biotech Corp. are higher in after-market trading, despite a slight decline earlier in the session and broader market weakness.

30 jul 2026, 22:41 UTC

Shares of Legend Biotech Corp are trading lower in after-market hours, continuing a trend of unusual weakness since Thursday's close.

29 jul 2026, 19:27 UTC

Social Media

Legend Biotech Corp shares are lower, extending a four-session decline. Raymond James projects a 12-month price target range of $58 to $86.

28 jul 2026, 22:56 UTC

Shares of Legend Biotech Corp are trading higher in after-market hours, despite no specific news identified. The broader market showed gains earlier in the day.

27 jul 2026, 23:16 UTC

Legend Biotech Corp shares are higher in after-market hours, having briefly reached a session high. The price remains below its 20-day moving average.

24 jul 2026, 19:16 UTC

News

UBS downgraded Legend Biotech Corp to Neutral and cut its price target to $28, contributing to a decline in shares during Friday's session.

22 jul 2026, 18:31 UTC

Legend Biotech Corp shares are lower today amid broader market weakness and rising geopolitical tensions, despite an earlier peak during the session.

21 jul 2026, 16:46 UTC

Legend Biotech Corp. shares are higher today, reaching a session peak amid rising crude oil prices, despite trading below its 20-day moving average.

20 jul 2026, 19:01 UTC

Legend Biotech Corp is trading higher during Monday's session, rebounding from an earlier low and showing strength after a week of declines.

Peer Vergelijking

Prijswijziging

Legend Biotech Corp ADR Prognose

Koersdoel

By TipRanks

175.38% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 52.35 USD 175.38%

Hoogste 80 USD

Laagste 28 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Legend Biotech Corp ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Legend Biotech Corp ADR - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Legend Biotech Corp ADR

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.